A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

BACKGROUND: In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy. In Japan, three different once-da...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Pulm Med
Päätekijät: Muraki, Masato, Kunita, Yuki, Shirahase, Ken, Yamazaki, Ryo, Hanada, Soichiro, Sawaguchi, Hirochiyo, Tohda, Yuji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7805049/
https://ncbi.nlm.nih.gov/pubmed/33441146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-021-01403-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia